Subject: BriaCell Continues Substantial Progress and Provides Fall 2018 Outlook

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
BriaCell Continues Substantial Progress and Provides Fall 2018 Outlook
Hot Stock to WatchHot Stock to Watch

Company: BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX-V: BCT)


Price: 0.102

Change (%): - 0.0004 (0.39)

Volume: 800

Dr. William Williams, BriaCell’s President & CEO, is Featured in an Exclusive New Audio Interview at

AUSTIN, Texas, Aug. 28, 2018 (GLOBE NEWSWIRE) -, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (OTCQB: BCTXF) (TSX-V: BCT), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President & CEO, Dr. William Williams, is featured in a new audio interview at, Inc.

The new Bricell interview can be heard at

Dr. Williams, BriaCell’s President & CEO, called in to to go over the highlights for the Company’s achievements in the summer of 2018 and the expected newsflow from BriaCell in the coming months. BriaCell is currently conducting an ongoing, multicenter, Phase IIa study of Bria-IMT™ (listed in as NCT03066947) in advanced breast cancer, as well as the combination study of Bria-IMT™ with pembrolizumab or ipilimumab (listed in as NCT03328026). The company recently announced the addition of the Cancer Center of Kansas (CCK) as a new clinical trial site. The addition of a new clinical site is expected to accelerate patient enrollment in both clinical trials. Additionally, the Company recently hired Dr. Sunkari, an experienced Scientist, to speed up the development of Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy for advanced breast cancer.

Enrollment for the Phase IIa study of Bria-IMT™, BriaCell’s lead clinical candidate, is on track and the Company continues to expect the interim data in Q3 2018.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks